Skip to main content

Advertisement

SpringerLink
Log in

Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We compared the relative efficacy of interferon beta (IFNβ) products and azathioprine (AZA) in the treatment of relapsing- remitting multiple sclerosis (RRMS). Ninety-four previously untreated patients of short duration with RRMS were randomly allocated to the two treatment groups. The first group received IFNβ products (Betaferon,Avonex or Rebif); the second group received AZA for 12 months. Response to treatment was assessed at 3, 6, and 12 months after starting therapy. The mean number of relapse during one year of the study was lower in the AZA group than in the IFNβ products group (0.28 vs. 0.64, P < 0.05).After 12 months, 57.4% of patients receiving IFNβ products remained relapse free compared with 76.6% of those given AZA. The Expanded Disability Status Scale (EDSS) decreased by 0.30 units in IFNβ-treated patients (P < 0.05) and 0.46 in AZAtreated patients (P < 0.001). Treatment with IFNβ products and AZA significantly reduces the relapse rate and EDSS score in patients with RRMS, while AZA is more effective than the IFNβ formulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Clark W (1996) Therapeutic advances: Interferon for multiple sclerosis. J Clin Pharm Ther 21:195–199

    Article  PubMed  CAS  Google Scholar 

  2. Clegg A, Bryant J, Milne R (2000) Disease- modifying drugs for multiple sclerosis: a rapid systematic review. Health Technol Assess 4:9–25

    Google Scholar 

  3. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231

    Article  PubMed  Google Scholar 

  4. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G (1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46:1607–1612

    PubMed  CAS  Google Scholar 

  5. Etemadifar M, Janghorbani M, Shaygannejad V (2006) Comparison of betaferon, avonex and rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand 113:283–287

    Article  PubMed  CAS  Google Scholar 

  6. Fernández O, Fernández V, De Ramón E (2004) Azathioprine and methotrexate in multiple sclerosis. J Neurol Sci 223:29–34

    Article  PubMed  CAS  Google Scholar 

  7. Filippini G, Munari L, Incorvaia B, et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552

    Article  PubMed  CAS  Google Scholar 

  8. Frank JA, Richert N, Bash C, et al. (2004) Interferon-beta-1b slows progression of atrophy in RRMS: Threeyear follow-up in NAb– and NAb+ patients. Neurology 62:719–725

    PubMed  CAS  Google Scholar 

  9. Goodin DS, Frohman EM, Gammany Jr GP, et al. (2002) Disease modifying therapies in multiple sclerosis: reports of therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guideline. Neurology 58:169–178

    PubMed  CAS  Google Scholar 

  10. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW (1991) The efficacy of azathioprine in relapsingremitting multiple sclerosis. Neurology 41:20–25

    PubMed  CAS  Google Scholar 

  11. IFN β Multiple Sclerosis Study Group, Interferon β-1b is effective in relapsing- remitting multiple sclerosis: I (1993) Clinical results of a multicentre, randomized, double-blind, placebo controlled trial.Neurology 43:655–661

    Google Scholar 

  12. IFN β Multiple Sclerosis Study Group University of British Columbia MS/MRI (1995) Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial.Neurology 45:1277–1285

    Google Scholar 

  13. Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294

    Article  PubMed  CAS  Google Scholar 

  14. Jacobs L, Rudick R, Simon J (2000) Extended observations on MS patients treated with IM interferon-1a (Avonex™): implications for modern MS trials and therapeutics. J Neuroimmunol 107:167–173

    Article  PubMed  CAS  Google Scholar 

  15. Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(Suppl 1A):44–49

    Article  PubMed  CAS  Google Scholar 

  16. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    PubMed  CAS  Google Scholar 

  17. Lhermitte F, Marteau R, Roullet R (1984).Not so benign long-term immunosuppression in multiple sclerosis. Lancet I:276–277

    Article  Google Scholar 

  18. Lublin FD,Whitaker JN, Eideman BH, Miller AE, Arnason BG, Burks JS (1996) Management of patients receiving Interferon β-1b for multiple sclerosis: report of a consensus conference. Neurology 46:12–18

    PubMed  CAS  Google Scholar 

  19. Massacesi L, Parigi A, Barilaro A, et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62:1843–1847

    Article  PubMed  Google Scholar 

  20. Mertin J, Kremer M, Knight SC, et al. (1982) Double blind controlled trial of immunosuppressant in the treatment of multiple sclerosis: final report. Lancet II:351–354

    Article  Google Scholar 

  21. Milanese C, La Mantia L, Salmaggi A, Caputo D (2001) Azathioprine and interferon beta-1b treatment in relapsing- remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:413–414

    Article  PubMed  CAS  Google Scholar 

  22. Milanese C, La Mantia L, Salmaggi A, Eoli M (1993) A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol 240:295–298

    Article  PubMed  CAS  Google Scholar 

  23. Palace J, Rothwell P (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350:261

    Article  PubMed  CAS  Google Scholar 

  24. Patzold U, Hecker H, Pocklington P (1982) Azathioprine in treatment of multiple sclerosis. J Neurol Sci 54:377–394

    Article  PubMed  CAS  Google Scholar 

  25. Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guideline for research protocol. Ann Neurol 13:227–231

    Article  PubMed  CAS  Google Scholar 

  26. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (1998) Randomized double-blind placebo-controlled study of Interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  27. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis (1998) PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498–1504

    Article  Google Scholar 

  28. Rice G, Ebers GC (1998) Interferons in the treatment of multiple sclerosis. Do they prevent the progression of the disease? Arch Neurol 55:1578–1580

    Article  PubMed  CAS  Google Scholar 

  29. Rice G, Incorvais B, Munari L, et al. (2001) A Cochrane review of recombinant interferons trials in relapsing remitting multiple sclerosis. J Neurol 248(Suppl 2):II/62

    Google Scholar 

  30. Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z (2005) Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese RRMS patients: a randomized,multicenter study. Neurology 64:621–630

    PubMed  CAS  Google Scholar 

  31. Schultz K, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412

    Article  Google Scholar 

  32. Sudlow CL, Counsell CE (2003) Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. Br Med J 326: 388–392

    Article  Google Scholar 

  33. Wroe SJ (2005) Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 33:309–318

    PubMed  CAS  Google Scholar 

  34. Yudkin PL, Ellison GW, Ghezzi A, et al. (1991) Overview of AZA treatment in multiple sclerosis. Lancet 338:1051–1055

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology and Epidemiology, Isfahan University of Medical Sciences and Health Services, Iran

    M. Etemadifar,  M. Janghorbani & V. Shaygannejad

  2. Dept. of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

    M. Janghorbani

Authors
  1. M. Etemadifar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Janghorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Shaygannejad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Janghorbani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Etemadifar, M., Janghorbani, M. & Shaygannejad, V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 254, 1723–1728 (2007). https://doi.org/10.1007/s00415-007-0637-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-007-0637-1

Key words

Search

Navigation